

Nima Rezaei
Editor

Cancer Immunology

Bench to Bedside
Immunotherapy of Cancers

 Springer

Cancer Immunology

Nima Rezaei
Editor

Cancer Immunology

Bench to Bedside
Immunotherapy of Cancers

 Springer

Editor

Nima Rezaei, MD, PhD
Research Center for Immunodeficiencies
Children's Medical Center
Pediatrics Center of Excellence
Tehran University of Medical Sciences
Tehran
Iran

Department of Immunology
School of Medicine
and Molecular Immunology
Research Center
Tehran University of Medical Sciences
Tehran
Iran

ISBN 978-3-662-44945-5 ISBN 978-3-662-44946-2 (eBook)
DOI 10.1007/978-3-662-44946-2
Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014952677

© Springer-Verlag Berlin Heidelberg 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

This book would not have been possible without the continuous encouragement by my parents and my wife, Maryam.

I wish to dedicate it to my daughters, Ariana and Arnika, with the hope that progress in the diagnosis and treatment of these diseases may result in improved survival and quality of life for the next generations and at the same time that international collaboration in research will happen without barriers.

Whatever I have learnt comes from my mentors. This book is therefore dedicated also to all of them, but most importantly to the patients and their families whose continuous support has guided me during the years.

Foreword



Several empirical observations suggested a long time ago that established human tumors could melt away in response to perturbations of the immune system such as during acute infection. Such regressions of tumors occurred most often but not exclusively when infection occurred at the tumor site and sparked the interest of investigators in identifying the mechanism leading to such occurrences based on the assumption that infection acted as an adjuvant to boost existing but insufficient immune surveillance against neoplasms. These anecdotal observations are reflected not only in the scientific literature such as the classic reports of William Cooley in the late 1800s but even discussed by classic authors such as the doctor-writer Anton Chekhov.

It took time, however, to elevate these concepts derived from empirical observations to a science of molecular precision. Skepticism dominated the scene for a long time including during the late 1980s, when the introduction of systemic IL-2 therapy for the treatment of advanced melanoma and renal cell carcinoma provided consistent and reproducible evidence that some advanced

cancers could regress and remain in long-term remission with a treatment that had for sure no direct effect on cancer cells. Retrospectively, as too often occurs in science, this skepticism was unwarranted, and the detractors of cancer immunotherapy made a disservice by slowing the progression of this budding discipline. Common criticisms were not directed against the observation that cancers could regress but rather focused on denial about the overall effectiveness of treatment, the sporadic nature of the regressions, and the relatively high toxicity. In other words, the skeptics confused the clinical effectiveness of a treatment with the value of a promising scientific observation.

I am emphasizing this because it is important to remember those difficult moments now that books as sophisticated and comprehensive are presented on a topic that was not even considered true science by most just a few decades ago. Fortunately, several investigators did not give up, but focusing on the value of an uncommon but reproducible observation carried the field forward.

Thus this book! An achievement difficult to predict only two decades ago!

A book series that encompassed 77 chapters spanning biological aspects of innate and adaptive immune responses to system biology approaches to biomarker discovery, to portrays of clinical successes and discussion of regulatory processes that are about to revolutionize the development and licensing of new investigational agents.

A significant change occurred after the identification and molecular characterization of antigens recognized by antibodies and/or T cells. Moreover, the characterization of molecular mechanisms controlling the cross talks between cancer and non-neoplastic somatic cells expanded the field and understanding of the mechanistic bases of immune-mediated tumor rejection. These unarguable observations gave molecular precision to what was previously perceived as pointless practice. However, the true revolution came with the clinical demonstration that some of the novel biological agents could significantly improve the survival of patients, receiving, therefore, acceptance and recognition as standard therapies through regulatory licensing.

Yet, challenges remain, and it is not the time to relax. Still, the benefits, though reproducible, are marginal both in terms of number of patients benefiting from the treatment and in the length of survival for those who benefit. Most importantly, the outcomes are capricious and unpredictable. Predictive and surrogate biomarkers are missing in spite of novel technologies and strategies that could help in the identification and stratification of patients. Still, most clinical trials are designed to look at outcomes rather than comprehensively learn in case of failures. Still, a gap exists between the potentials for what we could do to better understand the biology of immune responsiveness and what we actually do.

This book is written for those who want to move the field forward both at the clinical and the scientific level. Such a compendium can provide a contemporary overlook at what has happened lately, which is remarkably logarithmic on a time perspective. Yet, we wonder how elemental this edition may seem just within a few years if the field continues to evolve at the current pace. We hope that a second edition will follow soon. Perhaps the editors should have asked for a clairvoyant's chapter. Hopefully, one of the young readers of this edition may step forward and help define the new frontiers of cancer immunotherapy.

Preface



The rapid flow of studies in the field of cancer immunology during the last decade has increased our understanding of the interactions between the immune system and cancerous cells. In particular, it is now well known that such interactions result in the induction of epigenetic changes in cancerous cells and the selection of less immunogenic clones as well as alterations in immune responses. Understanding the cross-talk between nascent transformed cells and cells of the immune system has led to the development of combinatorial immunotherapeutic strategies to combat cancer.

Cancer Immunology Series, a three-volume book series, is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. The book *Cancer Immunology: A Translational Medicine Context*, is focused on the immunopathology of cancers. *Cancer Immunology: Bench to Bedside Immunotherapy of Cancers*, is a translation text explaining novel approaches in the immunotherapy of cancers. Finally, the book entitled *Cancer Immunology: Cancer*

Immunotherapy for Organ-Specific Tumors, thoroughly addresses the immunopathology and immunotherapy of organ-specific cancers.

In the book: *Cancer Immunology: Bench to Bedside Immunotherapy of Cancers*, clinical applications of cancer immunotherapy are fully described. Notably, the principal focus is very much on putting the basic knowledge gained on tumor immunology in volume I into a clinical perspective, with the aim to educate clinicians on the most recent approaches used in tumor immunotherapy.

Twenty-seven chapters are allocated in this regard. At the very beginning, an overview on frontiers in cancer immunotherapy is given in Chap. 1; then, novel strategies in cancer immunotherapy are discussed in Chap. 2. Thereafter, immunologic biomarkers possessing prognostic importance as well as tumor antigens valuable in the treatment and clinical evaluation of tumors are outlined in Chaps. 3 and 4, respectively.

Due to the importance of overcoming tumor immunosuppression and cancer tolerance when treating tumors, Chaps. 5 and 6 aim to tackle these crucial and challenging issues. From this point, more precise focus is given to introducing novel immunotherapeutic approaches by allocating Chaps. 7, 8, 9, and 10 to gene therapy, virus-based vaccines, cancer stem cells, hematopoietic stem cell transplantation, and lymphodepletion. Chapter 11 provides the readers with the most important details on the combination of chemotherapy and cytokine therapy in tumor management. Various aspects of the role of T lymphocytes in cancer immunotherapy are explained in Chaps. 12, 13, and 14, with special attention to their synthetic biology, clinical application, and roles in immunosurveillance and immunotherapy as well as in optimizing chemokine receptor-mediated homing of T cells in cancer immunotherapy.

Regulating B cells in order to provoke antitumor response and a general discussion on the multitude of monoclonal antibodies used in the clinical and preclinical setting are brought up in Chaps. 15 and 16, respectively. Chapter 17 aims to familiarize readers with the roles of pattern recognition receptors and Toll-like receptor pathway, while Chap. 18 discusses the role of NK cells in cancer immunotherapy. Novel vaccines produced by dendritic cells for cancer therapy are elucidated in Chap. 19. Thereafter, Chap. 20 explicates the role of tumor-associated macrophages in tumor development.

The implication of photodynamic therapy and polarization of the tumor milieu are brought up in the following two chapters, Chaps. 21 and 22, followed by Chap. 23 which discusses targeting 5T4 oncofetal glycoprotein as an immunotherapeutic approach. Novel biomarkers discovered during anti-CTLA4 antibody therapy are described in Chap. 24. Chapters 25 and 26 discuss radioimmunotherapy and psychoneuroendocrinotherapy, respectively. Finally, the book concludes by pointing to the ethical considerations crucial during cancer immunotherapy.

The Cancer Immunology series is the result of valuable contributions of more than 250 scientists from more than 100 well-known universities/institutes worldwide. I would like to hereby acknowledge the expertise of all contributors for generously devoting their time and considerable effort in preparing their respective chapters. I would also like to express my gratitude to Springer for providing me the opportunity to publish the book.

In the end, I hope that this translational book will be comprehensible, cogent, and of special value to researchers and clinicians who wish to extend their knowledge on cancer immunology.

Acknowledgment

I would like to express my gratitude to the technical editor of this book, Maryam Ebadi, MD. With no doubt, the book would not have been completed without her contribution.

Nima Rezaei, MD, PhD

Contents

1	Frontiers in Cancer Immunotherapy	1
	Joseph F. Murphy	
1.1	Introduction	1
1.2	Innate Cells as Initiators of the Adaptive Immune Response	2
1.3	Cellular Immunotherapy	2
1.4	Active and Passive Immunotherapy	2
1.4.1	Active Immunotherapy	3
1.4.2	Nonspecific Immunotherapy	3
1.5	Stimulation of Responses In Vivo	4
1.6	Adoptive Immunotherapy	5
1.7	Cancer Vaccines	6
1.7.1	Dendritic Cells	8
1.7.2	Physical Barriers, Tumor Stroma and Vessels	10
1.8	Mechanisms of Tumor-Induced Tolerance/Escape from the Immune System	11
1.8.1	Treg Cells	12
1.8.2	Myeloid-Derived Suppressor Cells	13
1.8.3	Macrophages	13
1.9	Candidates for Immunotherapy in Oncology	14
1.10	Combination Immunotherapy	14
1.10.1	Chemotherapy and mAb	15
1.10.2	Chemotherapy and Active Specific Immunotherapy	15
1.10.3	Chemotherapy and Adoptive Lymphocyte Immunotherapy	15
1.10.4	Immunotherapy with Radiation Therapy	16
1.11	Humoral Immunotherapy	16
1.12	Concluding Remarks	17
	References	17
2	Novel Strategy of Cancer Immunotherapy: Spiraling Up	23
	Lev V. Demidov, Irina Zh. Shubina, and Mikhail V. Kiselevsky	
2.1	Introduction	23
2.2	Natural Killer Cells: The Key Effectors of Innate Immunity	24
2.3	Adoptive IL-2/LAK (or CIK) Therapy of Cancer	26
2.4	Tumor-Infiltrating Lymphocytes (TILs) in Cancer Immunotherapy	27

2.5	Autologic Vaccines on the Base of Dendritic Cells (DC Vaccines)	29
2.6	Advantages of Combined Implication of DC Vaccines and Activated Lymphocytes	30
2.7	Spiral Up	30
2.8	Concluding Remarks	31
	References	31
3	Novel Prognostic Biomarkers for Personalized Cancer Treatment	35
	Ida Contasta, Anna Maria Berghella, Roberto Lattanzio, Osvaldo Ciccarelli, Giancarlo Di Gregorio, Maurizio Vizioli, Marino Silvino, Luigi Liborio Liberatore, Luca Navarra, Giampaolo Caterino, Antonio Mongelli, Vincenzo Vittorini, Irma Campitelli, Nunzia Antonucci, Tiziana Del Beato, Enzo Secinaro, and Patrizia Pellegrini	
3.1	Introduction	36
3.2	Presentation	37
3.3	New Biomarkers for the Treatment of Tumors	37
3.4	Guidelines for the Identifications of “Suitable” Biomarkers: A Healthy Longevity Is Linked to an Healthy Function of the Immune System. The Pathology Is Generated by Alterations of This System	40
3.5	The Importance of the Evaluation of Both Genders as Independent Groups	41
3.6	Men and Women Follow Different Strategies to Regulate the Homeostasis of the Immune System	41
	3.6.1 Variations of Pro- and Anti-inflammatory Cytokine Levels Regulate the Immune Response and Could Influence the Healthy State	41
	3.6.2 “Double Prognostic Biomarkers”: Appropriate Variations Between Pro- and Anti-Inflammatory Cytokines Assure the Success of the Immune Response but Following Different Gender Pathways	42
	3.6.3 The Efficiency of the Treatment Is Related to a Reestablishment of IL-6 Pathways in Women, and IFN- γ Pathways in Men	44
3.7	The Valuation of the Thioredoxin and CD30 Systems for the Prognostic, Diagnostic, and Therapeutic Stratification of Patients	44
	3.7.1 Trx1/RTx1 System	46
	3.7.2 The CD30/CD30L/sCD30 System	46
3.8	New “Double Biomarkers” That Are Prognostic for Patient Stratification and for the Personalized Therapies	47
3.9	Concluding Remarks	50
	References	50

4	Tumor Antigen and Epitope Identification for Preclinical and Clinical Evaluation	55
	Shraddha S. Rane, Jaimy Mariam Sultana Javad, and Robert C. Rees	
4.1	Introduction	55
4.2	Reverse Immunology Approach to Peptide Identification. . .	57
4.2.1	Target Antigen Identification	58
4.2.2	In Silico Peptide Predictions	59
4.2.3	Epitope Validation	61
4.3	Direct Immunology Approach	62
4.3.1	Isolation of Peptide–MHC Complexes	62
4.3.2	Analysis and Sequencing of MHC-Associated Peptides	62
4.4	Human Immunotherapy Against Tumor-Associated Peptides	63
4.5	Strategies to Enhance the Immunogenicity of Peptide Epitopes	65
4.5.1	Potential Adjuvants for Boosting Immune Responses	66
4.5.2	TLR Agonists in Cancer Vaccine Trials	66
4.6	Future Prospects	68
4.7	Concluding Remarks	69
	References	69
5	Strategies to Target Tumor Immunosuppression	73
	Oana Draghiciu, Hans W. Nijman, and Toos Daemen	
5.1	Introduction	73
5.2	The Balance Is Tilted: Mechanisms of Tumor Immune Escape	74
5.2.1	Tolerance Mechanisms	74
5.2.2	Immunosuppression Mechanisms	75
5.3	Shifting the Balance: Strategies to Target Tumor Immunosuppression	77
5.3.1	Strategies Targeting Homing of Effector T Cells . . .	77
5.3.2	Strategies Targeting the Activity of Effector T Cells	79
5.4	Concluding Remarks	81
	References	82
6	Overcoming Cancer Tolerance with Immune Checkpoint Blockade	87
	Guy T. Clifton, Elizabeth A. Mittendorf, and George E. Peoples	
6.1	Introduction	87
6.2	Cytotoxic T-Lymphocyte-Associated Antigen-4 (CTLA-4): A Paradigm for Immune Checkpoint Blockade	89

6.2.1	CTLA-4 Function	89
6.2.2	Preclinical Development of CTLA-4 Blocking Therapy	92
6.2.3	CTLA-4 Blockade Monotherapy in Melanoma	93
6.2.4	Toxicity	97
6.2.5	Immune-Related Response Criteria	98
6.2.6	CTLA-4 Blockade in Cancers Other than Cutaneous Melanoma	98
6.2.7	CTLA-4 Blockade as Combination Therapy	100
6.3	Programmed Death 1 (PD-1) Pathway	104
6.3.1	Function	104
6.3.2	PD-1 Pathway in Cancer	105
6.3.3	PD-1 Blockade	106
6.3.4	PD-L1 Blockade	107
6.4	Combination Immunotherapy	108
6.4.1	CTLA-4 Blockade and Vaccination	108
6.4.2	CTLA-4 Blockade and Cytokine Therapy	109
6.4.3	Combination Checkpoint Blockade	110
6.5	Other Checkpoint Pathways Under Development	110
6.5.1	Lymphocyte Activation Gene-3 (LAG-3)	110
6.5.2	4-1BB	111
6.5.3	OX-40	112
6.5.4	Glucocorticoid-Induced TNFR Related Protein (GITR)	113
6.5.5	CD40	114
6.5.6	TGN1421: A Cautionary Tale	115
6.6	Concluding Remarks	116
	References	116
7	Gene Therapy and Virus-Based Cancer Vaccines	131
	Mohamed Labib Salem, Kamal Kamal Elsayed Gadalla, Burtram C. Fielding, and Steve H. Thorne	
7.1	Introduction	131
7.2	Viral Vectors Used in Cancer Gene Therapy	132
7.2.1	Retrovirus Vectors (RVVs)	132
7.2.2	Poxvirus Vectors (PVVs)	135
7.2.3	Adenoviral Vectors (AdVVs)	135
7.2.4	Adeno-Associated Virus Vector (AAVVs)	136
7.2.5	Herpes Simplex Virus Type 1 Vectors (HSVVs)	136
7.3	Non-viral Methods of Gene Delivery	137
7.3.1	Delivery of Plasmid DNA	137
7.4	Cancer Gene Therapy	138
7.4.1	Oncogene and Tumor Suppressor Gene Targeted Gene Therapy	138
7.4.2	Enhancing Pro-Drug Cytotoxicity in the Tumor Cells Through Gene Therapy	140

7.4.3	Thymidine Kinase (TK)	140
7.4.4	Cytosine Deaminase (CD)	141
7.5	Anti-angiogenesis Gene Therapy	141
7.6	Cancer Vaccines and Vaccine Production	141
7.6.1	Virus-Based Vaccines	142
7.7	Oncolytic Viruses	142
7.7.1	Mechanism of Action	143
7.7.2	Viral Agents Used as Oncolytic Agents	144
7.8	Concluding Remarks	144
	References	144
8	Cancer Stem Cells: Biology and Potential Therapeutic Applications	151
	Monica Mangoni, Mariangela Sottili, Mauro Loi, Chiara Gerini, Icro Meattini, and Lorenzo Livi	
8.1	Introduction	151
8.2	Identification and Characterization of Cancer Stem Cells	152
8.2.1	Surface Markers	152
8.2.2	Side Population	153
8.2.3	ALDEFLUOR Assay	153
8.2.4	Sphere-Forming Assay	154
8.2.5	Signaling Pathways	154
8.3	A Dynamic Cancer Stem Cell Concept	156
8.4	The CSCs Niche	157
8.4.1	Functions	157
8.4.2	CSC Niche as Therapeutic Target	158
8.5	CSCs in Tumor Invasion and Metastasis	158
8.5.1	CSCs, EMT, and Metastasis	159
8.5.2	Signaling Pathways Involved in Metastasis	159
8.5.3	Premetastatic Niche	161
8.6	Tracking CSCs	161
8.7	CSC Resistance: Clinical Implications	163
8.7.1	Enhanced DNA Repair	163
8.7.2	Free-Radical Scavenging	164
8.7.3	Quiescence	164
8.7.4	Signaling Pathways	164
8.8	Perspectives in Radiation Oncology	165
8.9	Concluding Remarks	166
	References	166
9	Immunologic Approaches to Targeting Cancer Stem Cells	177
	Qin Pan, Qiao Li, Ning Ning, Yingxin Xu, Alfred E. Chang, and Max S. Wicha	
9.1	Introduction	178
9.2	ALDEFLUOR ⁺ /ALDH ^{high} Serves as a Specific Marker for Cancer Stem Cells in Multiple Tumor Types	178

9.3	Cancer Stem Cells Are Resistant to Conventional Tumor Therapies	179
9.4	Innate Immune Response to Cancer Stem Cells	180
9.5	Cancer Stem Cell-Primed T Cells Specifically Targeting Cancer Stem Cells	181
9.6	Development of Cancer Stem Cell-Specific Vaccine in Immunocompetent Host	182
9.7	Targeting the Tumor Microenvironment as a Strategy to Enhance Immunological Targeting of Cancer Stem Cells	184
9.8	Concluding Remarks	185
	References	185
10	Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer	189
	Kristen M. Barr, Jill A. Gershan, and Bryon D. Johnson	
10.1	Introduction	189
10.2	Hematopoietic Stem Cell Transplantation (HSCT)	190
10.2.1	Sources of Hematopoietic Stem Cells (HSCs)	190
10.2.2	Autologous and Allogeneic HSCT	190
10.2.3	Graft-Versus-Host Disease and the Graft Versus Tumor Effect	191
10.2.4	Myeloablative Effects That Promote the Elimination of Hematologic Malignancies	193
10.2.5	Non-myeloablative Conditioning	194
10.3	Lymphodepletion for the Treatment of Solid Tumors	195
10.3.1	Lymphodepletion-Induced T Cell Thymopoiesis Is Important for Reconstitution of the T Cell Repertoire	196
10.3.2	Lymphodepletion-Induced Homeostatic Proliferation as Strategy to Augment Antitumor Immunity	196
10.3.3	Use of Animal Models to Address Immunological Effects of Lymphodepletion	197
10.4	Concluding Remarks	198
	References	198
11	Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers	203
	Mariana Malvicini, Manglio M. Rizzo, Laura Alaniz, and Guillermo D. Mazzolini	
11.1	Introduction	203
11.2	Immune Response in the Control of Cancer	204
11.2.1	Cancer Immunoediting Theory	204
11.2.2	Tumors Escape from the Host Immune Response	205

11.3	Immunotherapy of Cancer	206
11.3.1	Enhancing Antitumor Immunity Using Cytokines	206
11.4	Overcoming Tumor Resistance and the Use of Chemotherapeutic Agents	207
11.4.1	Chemotherapy Plus Immunotherapy	208
11.4.2	Rationale for Drug Selection	208
11.5	Combined Therapies	209
11.5.1	Preclinical Experience	209
11.5.2	What Have We Learned from the Clinical Practice?	210
11.6	Concluding Remarks	212
	References	212
12	T Cell Immunotherapy: From Synthetic Biology to Clinical Practice	217
	Ling Zhang and Rimas J. Orentas	
12.1	Introduction	217
12.2	T Cell Responses to Cancer	218
12.3	From Polyclonal to Single-Specificity Effector T Cells	218
12.4	From MHC to Antibody-Based Recognition: Therapy with T Cells Expressing CARs	220
12.4.1	History of CAR Development	220
12.4.2	Inclusion of T Cell Signaling Moieties	220
12.4.3	Vectors Used for CAR Expression	221
12.4.4	Impact of T Cell Culture and Expansion Techniques	223
12.4.5	Clinical Advances with CAR Therapy	224
12.5	Concluding Remarks	226
	References	226
13	Role of $\gamma\delta$ T Lymphocytes in Cancer Immunosurveillance and Immunotherapy	231
	Telma Lança, Daniel V. Correia, and Bruno Silva-Santos	
13.1	Introduction	231
13.2	TCR $\gamma\delta$ Repertoires and Functions	232
13.2.1	Mouse $\gamma\delta$ T-Cell Subsets	233
13.2.2	Human $\gamma\delta$ T-Cell Subsets	233
13.3	$\gamma\delta$ T-Cell Activation: TCR $\gamma\delta$ Agonists	234
13.3.1	Phosphoagonists (Phosphoantigens)	234
13.3.2	Aminobisphosphonates	236
13.3.3	Alkylamines	236
13.3.4	Protein Ligands	236
13.4	$\gamma\delta$ T-Cell Activation: Costimulatory Molecules	238
13.4.1	CD27	238
13.4.2	CD28	238
13.4.3	Fc Receptors: CD16	239

13.5	$\gamma\delta$ T-Cell Activation via Natural Killer Receptors (NKRs)	240
13.5.1	NKG2D	240
13.5.2	NKG2A	243
13.5.3	Natural Cytotoxicity Receptors (NCRs)	243
13.5.4	DNAM-1	244
13.6	Tumor Cell Recognition by $\gamma\delta$ T Cells: TCRs Versus NKRs	244
13.7	$\gamma\delta$ T-Cell Responses to Tumors	245
13.7.1	Antitumor Properties	245
13.7.2	Pro-tumor Properties	247
13.8	$\gamma\delta$ T-Cell Modulation in Cancer Clinical Trials	248
13.9	Concluding Remarks	249
	References	252
14	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy	263
	Imran Siddiqui, Alberto Mantovani, and Paola Allavena	
14.1	Introduction	263
14.2	History of Adoptive Immunotherapy of Malignancy	265
14.3	T-Cell Infiltration Correlates with Prognosis	265
14.4	Adoptive T-Cell Therapy	266
14.5	Challenges in Adoptive T-Cell Therapy	267
14.6	Chemokines	268
14.7	The Role of Chemokines in Directing Tissue Trafficking in Tumors	268
14.8	Overexpression of Chemokine Receptors in Engineered Lymphocytes to Be Used for Cancer Immunotherapy	271
14.9	Concluding Remarks	274
	References	275
15	B Cell Regulation of Antitumor Response	283
	Ahmed Al Bayati, Yu Zhang, and Joseph D. Rosenblatt	
15.1	Introduction	283
15.2	Mechanisms Underlying B Cell Modulation of Antitumor Immune Response	286
15.3	B Cells and the Role of Tregs	286
15.4	B-Regulatory Cell Infiltration into Human Tumors	288
15.5	Breg Function in Non-Hodgkin Lymphoma	288
15.6	Effects of Depletion of B Cells on Antitumor Immunity	289
15.7	Concluding Remarks	290
	References	290

16 Monoclonal Antibodies for Cancer Immunotherapy	293
Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh, and Mahmood Jeddi-Tehrani	
16.1 Introduction	294
16.2 Structural and Functional Features of Antibodies	294
16.3 Natural Antibodies in Cancer	295
16.4 Finding an Appropriate Antibody Target for Cancer Therapy	296
16.4.1 Characteristics of a Favorable Cell Surface Antigen	296
16.4.2 Classification of Cancer Antigens	296
16.4.3 Target Identification Approaches	296
16.5 Molecular Mechanisms Involved in Monoclonal Antibody-Based Therapy	299
16.5.1 Direct Tumor Cell Elimination	299
16.5.2 Harnessing the Potential Capacity of Immune System to Eliminate Tumors	299
16.5.3 Targeting Tumor Stroma and Vasculature	301
16.6 Engineered Antibodies	302
16.6.1 Murine Monoclonal Antibodies	302
16.6.2 Chimeric and Humanized Monoclonal Antibodies	303
16.6.3 Fully Human Monoclonal Antibodies	303
16.6.4 Antibody Fragments	304
16.6.5 Bispecific Antibodies (BsAbs)	306
16.6.6 Antibody Fusion Constructs	307
16.6.7 Improvement of Antibody Function	307
16.7 Evaluation of Antibody Efficacy	308
16.7.1 Preclinical Evaluations	308
16.7.2 Clinical Evaluations	308
16.8 Clinically-Approved Monoclonal Antibodies	308
16.8.1 Trastuzumab	309
16.8.2 Bevacizumab	309
16.8.3 Rituximab	310
16.8.4 Therapeutic Monoclonal Antibodies Approved by Non-FDA Organizations	310
16.9 Monoclonal Antibodies Currently Undergoing Clinical Trials	311
16.10 Combinational Monoclonal Antibody-Based Modalities	311
16.10.1 Combination with Chemotherapy	311
16.10.2 Combination with Radiotherapy	312
16.10.3 Combination with Other Immunotherapeutic Methods	313
16.10.4 Other Combinational Approaches	313

16.11	Current Limitations in Monoclonal Antibody-Based Therapies	313
16.11.1	Tumor Escape	313
16.11.2	Relatively Low Single Agent Activity	314
16.11.3	Low Tissue Penetration	314
16.11.4	Fc-Fc Receptor Interactions and Associated Limitations	314
16.11.5	High Production Cost	315
16.12	Concluding Remarks	315
	References	315
17	Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers	329
	Seyed Hossein Aalaei-Andabili, Shaherin Basith, Sangdun Choi, and Nima Rezaei	
17.1	Introduction	329
17.2	TLRs Play Important Roles in Human Carcinogenesis	330
17.3	TLR Regulates Tumor-Induced Immune System Response	331
17.4	TLR Targeting May Inhibit Cancer Cell Proliferation	333
17.5	TLR Triggering Can Promote Antitumor Response	333
17.6	Regulatory Effects of TLRs on PI3K/Akt Signaling Controlling Tumor Progression	334
17.7	TLR-Mediated Hypoxia-Inducible Factor 1 (HIF-1) Expression Leads to Tumor Progression	334
17.8	Role of TLRs in Tumor Cell Lysis and Apoptosis	335
17.9	TLRs are Involved in Tumor Metastasis	335
17.10	Concluding Remarks	336
	References	337
18	Recent Advances in the Use of NK Cells Against Cancer	341
	Amy E. Gillgrass, Tamara Krneta, and Ali A. Ashkar	
18.1	Introduction	341
18.2	NK Cell Basics	342
18.2.1	How Do NK Cells Become Activated to Kill?	342
18.2.2	Why Should NK Cells Be Targeted as Anticancer Agents?	343
18.3	Challenges Involved in Targeting NK Cells	343
18.3.1	How Many NK Cells Are in Cancer Patients and Tumors?	343
18.3.2	What Is the Functionality of NK Cells in Tumors?	344
18.4	Cancer Immunotherapies Involving NK Cells	345
18.5	Adoptive NK Cell Transfer	346
18.5.1	How Can We Produce Large Numbers of Activated NK Cells?	346

18.6	Autologous Transfer of NK Cells	347
18.7	Allogeneic Transfer of NK Cells	348
18.8	NK Cell Lines for Allogeneic Adoptive Transfer.	349
18.9	NK Cells, ADCC, and mAb Therapy	349
18.10	Cytokines and Promoting NK Activation/Stopping Inhibition.	351
18.11	Concluding Remarks	352
	References	353
19	Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials	359
	Graziela Gorete Romagnoli and Ramon Kaneno	
19.1	Introduction.	359
19.2	Strategies for Developing Clinical Grade DC Vaccines	361
19.3	Routes of Administration	363
19.4	DC Vaccine for Prostatic Cancer	363
19.5	DC Vaccine for Melanoma	364
19.6	DC Vaccine for Colorectal Cancer	365
19.7	DC Vaccine for Nervous Tissue Cancer	366
19.8	Concluding Remarks.	367
	References	367
20	Tumor-Associated Macrophages and Cancer Development	375
	Ken-ichi Isobe and Hengyi Xiao	
20.1	Introduction.	375
20.2	Cancer and Inflammation	376
20.3	Development of Myeloid Lineage Cells Including Macrophages.	378
20.4	Characteristics of TAMs	379
20.5	“Reeducating” TAMs to Cytotoxic Phenotype.	379
20.6	Concluding Remarks.	380
	References	380
21	Photodynamic Therapy and Antitumor Immune Response	383
	Fatma Vatansever and Michael R. Hamblin	
21.1	Introduction.	383
21.2	Photodynamic Therapy.	384
21.3	Closer Look Up at the PDT and Triggered Immune Response	385
21.4	Significance of PDT and Adaptive Immunity.	387
21.5	Mechanism of PDT Immunologic Effects	387
21.6	Case Studies	388
21.7	Concluding Remarks.	394
	References	395

22 Polarization of Tumor Milieu: Therapeutic Implications	401
Stanisław Szala, Magdalena Jarosz-Biej, Tomasz Cichoń, Ryszard Smolarczyk, and Aleksander Sochanik	
22.1 Introduction	401
22.2 Recruitment of Inflammatory Cells by Cancer Cells	402
22.3 Macrophage Plasticity: M1 and M2 Phenotypes	403
22.4 TAM: Cells with M2 Phenotype	403
22.5 M1 → M2 Tumor Microenvironment Reversal: Therapeutic Approach	405
22.6 Concluding Remarks	406
References	406
23 Immunotherapies Targeting a Tumor-Associated Antigen, 5T4 Oncofetal Glycoprotein	409
Peter L. Stern	
23.1 Introduction	409
23.1.1 5T4 Trophoblast Glycoprotein Is an Oncofetal Antigen	409
23.2 5T4 and Epithelial Mesenchymal Transition (EMT)	411
23.3 5T4 Modulation of Chemokine and Wnt Signaling Pathways	411
23.4 Vaccines	412
23.4.1 Preclinical Studies	413
23.4.2 Early-Phase Clinical Trials of MVA-h5T4 (TroVax)	413
23.4.3 TroVax Phase III Clinical Trial in RCC	414
23.4.4 Insights from the 5T4 KO Mouse	415
23.4.5 Improving Vaccine Regimens	416
23.5 5T4 Antibody-Targeted Superantigen Therapy	416
23.5.1 Preclinical Studies	417
23.5.2 Early-Phase Clinical Studies	417
23.5.3 A Phase II/III Clinical Trial in RCC	418
23.6 Other 5T4 Antibody-Targeted Therapies	418
23.6.1 Antibody-Drug Conjugates (ADC)	418
23.6.2 Direct 5T4 Antibody Effects	419
23.6.3 5T4 Chimeric Antigen Receptors	420
23.7 Concluding Remarks	421
References	421
24 Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy	427
Geoffery Y. Ku, Chrisann Kyi, and Jianda Yuan	
24.1 Introduction	427
24.2 Absolute Lymphocyte Count	428
24.3 Analyses of Different Cell Populations in Peripheral Blood	429
24.3.1 T Cell Activation Markers	429
24.3.2 Regulatory T Cells	429
24.3.3 Myeloid-Derived Suppressor Cells (MDSCs)	430

24.4	Antigen-Specific Immunological Monitoring	430
24.4.1	Antigen-Specific Antibody Response	431
24.4.2	Antigen-Specific T Cell Response	431
24.5	Analyses of Specific T Cell Populations in the Tumor Microenvironment	432
24.6	Future Perspectives	433
24.7	Concluding Remarks	434
	References	435
25	New Advances in Radioimmunotherapy for the Treatment of Cancers	441
	Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, Thomas Carlier, Ludovic Ferrer, Nicolas Chouin, Férid Haddad, François Davodeau, Jean-François Chatal, Alain Faivre-Chauvet, Jean-François Gestin, Michel Chérel, and Jacques Barbet	
25.1	Introduction	442
25.2	Principles of Radioimmunotherapy	442
25.3	Radionuclides and Radiolabeling Techniques for Therapy	443
25.3.1	Radionuclides	443
25.3.2	Labeling Techniques	444
25.4	The Treatment of B Cell Lymphoma with Anti-CD20 Antibodies	446
25.5	Promising Results in Hemopathies Using Other Antibodies	447
25.5.1	Targeting of Lymphoma with Anti-CD22 Antibodies	447
25.5.2	Targeting of Multiple Myeloma Using Anti-CD138 Antibodies	448
25.6	RIT of Metastatic Prostate Cancer	449
25.7	RIT with Alpha-Emitting Radionuclides	450
25.7.1	Therapeutic Indication	450
25.7.2	Limited Availability	451
25.7.3	Issues and Current Developments	451
25.8	High Efficacy of Pretargeting Approaches in Metastatic Thyroid Carcinoma	451
25.9	Immuno-PET: The Future for Dosimetry Assessment and Patient Selection	452
25.9.1	Immuno-PET and Development of New Drugs	453
25.9.2	Patient Selection for Therapy	453
25.9.3	Determination of the Cumulated Activity Concentration for RIT	453
25.9.4	Therapy Response	454
25.10	Concluding Remarks	454
	References	454

26 Psychoneuroendocrinoimmunotherapy of Cancer	461
Paolo Lissoni, Giusy Messina, and Franco Rovelli	
26.1 Introduction.....	461
26.2 The Physiopathology of Anticancer Immunity.....	462
26.3 The Fundamental Phases of Tumor Onset and Dissemination.....	463
26.4 Main Cancer-Related Immunoneuroendocrine Alterations.....	464
26.5 Preliminary Clinically Applied PNEI Strategies	464
26.6 Future Perspectives.....	465
26.7 Concluding Remarks	466
References	466
27 Ethical Considerations in Cancer Immunotherapy	469
Maurie Markman	
27.1 Introduction.....	442
27.2 Ethical Issues in Immunotherapy of Cancer.....	470
27.3 Unique Toxicities	470
27.4 Evaluation of Efficacy in the Clinical Trial and Non-research Settings.....	470
27.5 Ethical Justification for Initiation of Treatment in Individual Patients.....	471
27.6 Concluding Remarks.....	472
References	472
Index	473

Contributors

Seyed Hossein Aalaei-Andabili, MD Thoracic and Cardiovascular Surgery, Department of Surgery, College of Medicine, University of Florida, Gainesville, Florida, USA

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Ahmed Al Bayati, BS Division of Hematology/Oncology, Department of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

Laura Alaniz, PhD Gene Therapy Laboratory, Department of Medicine, Hospital Universitario Austral, Derqui-Pilar, Buenos Aires, Argentina

Gene Therapy Laboratory, School of Biomedical Sciences, Austral University, Pilar, Buenos Aires, Argentina

Paola Allavena, MD Department of Immunology and Inflammation, Clinical and Research Institute Humanitas, Rozzano, Milan, Italy

Nunzia Antonucci, BSc Dipartimento di Chirurgia Generale, Ospedale SS Trinità, Popoli (PE), Italy

Ali A. Ashkar, DVM, PhD Department of Pathology and Molecular Medicine, McMaster Immunology Research Center (MIRC), McMaster University, Hamilton, ON, Canada

Jacques Barbet, PhD Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, Nantes, France

Subatech, Ecole des Mînes, University of Nantes, Nantes, France

GIP Arronax, Saint-Herblain, France

Kristen M. Barr, BS, PhD Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

Leila Barzegar-Yarmohammadi, MSc Monoclonal Antibody Research Center, Avicenna Research Institute ACECR, Tehran, Iran

Shaherin Basith, PhD Department of Molecular Science and Technology, College of Natural Science, Ajou University, Suwon, South Korea

Anna Maria Berghella, PhD Department of Medicine,
National Research Council-Institute of Translational Pharmacology,
Istituto di Farmacologia Traslazionale (IFT), Consiglio Nazionale delle
Ricerche (CNR), Unità Operativa di Supporto (UOS), L'Aquila, Italy

Caroline Bodet-Milin, MD Department of Nuclear Medicine
CHU de Nantes, Centre de Recherche en Cancérologie de Nantes-Angers
Inserm, Université de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau,
Saint-Herblain, France

Mahmood Bozorgmehr, PhD Nanobiotechnology Research Center,
Avicenna Research Institute, ACECR, Tehran, Iran

Irma Campitelli Laboratorio di Analisi Cliniche, Ospedale SS Trinità,
Popoli (PE), Italy

Thomas Carlier, PhD Department of Nuclear Medicine CHU de Nantes,
Centre de Recherche en Cancérologie de Nantes-Angers Inserm,
Université de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau,
Saint-Herblain, France

Giampaolo Caterino, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Alfred E. Chang, MD Division of Surgical Oncology,
Department of Surgery, University of Michigan
Comprehensive Cancer Center, Ann Arbor, MI, USA

Jean-François Chatal, MD, PhD GIP Arronax, Saint-Herblain, France

Michel Chérel, PD, PhD Department of Nuclear Medicine ICO-René
Gauducheau, Centre de Recherche en Cancérologie de Nantes-Angers
Inserm, Université de Nantes, Nantes, France

Department of Nuclear Medicine, University Hospital,
CHU de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau,
Saint-Herblain, France

INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13),
Institut de Recherche en Santé de l'Université de Nantes, Nantes, France

Sangdun Choi, PhD Department of Molecular Science and Technology,
College of Natural Science, Ajou University, Suwon, South Korea

Nicolas Chouin, PhD AMaROC Research Group, ONIRIS (Nantes-
Atlantic National College of Veterinary Medicine, Food Science and
Engineering), Nantes, France

Oswaldo Ciccarelli, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Tomasz Cichoń, PhD Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

Guy T. Clifton, MD General Surgery Department, Blanchfield Army Community Hospital, Fort Campbell, KY, USA

Fort Campbell Army Community Hospital, Fort Campbell, KY, USA

Ida Contasta, PhD Department of Medicine, National Research Council-Institute of Translational Pharmacology, Istituto di Farmacologia Traslazionale (IFT), Consiglio Nazionale delle Ricerche (CNR), Unità Operativa di Supporto (UOS), L'Aquila, Italy

Daniel V. Correia, PhD Department of T Cell Differentiation Faculdade de Medicina, Instituto de Medicina Molecular, Lisbon, Portugal

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Toos Daemen, PhD Department of Medical Microbiology, Section of Tumor Virology and Cancer Immunotherapy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

François Davodeau, PhD Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, Nantes, France

Tiziana Del Beato Department of Medicine, National Research Council-Institute of Translational Pharmacology, Istituto di Farmacologia Traslazionale (IFT), Consiglio Nazionale delle Ricerche (CNR), Unità Operativa di Supporto (UOS), L'Aquila, Italy

Lev V. Demidov, MD, PhD Department of Biotherapy of Tumors, N.N. Blokhin Russian Cancer Research Center RAMS, Moscow, Russia

Giancarlo Di Gregorio, PhD Laboratorio di Analisi Cliniche, Ospedale SS Trinità, Popoli (PE), Italy

Oana Draghiciu, MSc, PhD Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Alain Faivre-Chauvet, PD, PhD Department of Nuclear Medicine, Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, Nantes, France

Ludovic Ferrer, PhD Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, Nantes, France

Department of Nuclear Medicine, University Hospital, CHU de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau, Saint-Herblain, France

Burtram C. Fielding, PhD Department of Medical Biosciences, University of the Western Cape, Bellville, Cape Town, South Africa

Kamal Kamal Elsayed Gadalla, MBChB, MSc, MD, PhD Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Chiara Gerini, MS Radiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Jill A. Gershan, PhD Division of Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

Jean-François Gestin, PhD Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, Nantes, France

INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Santé de l'Université de Nantes, Nantes, France

Fatemeh Ghaemimanesh, PhD Monoclonal Antibody Research Center, Avicenna Research Institute ACECR, Tehran, Iran

Amy E. Gillgrass, MSc, PhD, BSc Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada

Férid Haddad, PhD Subatech, Ecole des Mines, University of Nantes, Nantes, France

GIP Arronax, Saint-Herblain, France

Michael R. Hamblin, PhD Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA

Department of Dermatology, Harvard Medical School, Boston, MA, USA

Department of Dermatology, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA

Ken-ichi Isobe, MD, PhD Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Magdalena Jarosz-Biej, PhD Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

Mahmood Jeddi-Tehrani, PhD Monoclonal Antibody Research Center,
Avicenna Research Institute ACECR, Tehran, Iran

Bryon D. Johnson, PhD Division of Hematology/Oncology,
Department of Pediatrics, Medical College of Wisconsin,
Milwaukee, WI, USA

Ramon Kaneno, PhD Department of Microbiology and Immunology,
Institute of Biosciences of Botucatu – UNESP, Univ Estadual Paulista,
Botucatu, SP, Brazil

Mikhail V. Kiselevsky, MD, PhD, Dr.Sc. Laboratory of Cell Immunity,
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow, Russia

Françoise Kraeber-Bodéré, MD, PhD Centre de Recherche en
Cancérologie de Nantes-Angers Inserm, Université de Nantes,
Nantes, France

Department of Nuclear Medicine, University Hospital,
CHU de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau,
Saint-Herblain, France

T. Krneta, BSc, MSc Department of Pathology and Molecular Medicine,
McMaster Immunology Research Center (MIRC), McMaster University,
Hamilton, ON, Canada

Geoffery Y. Ku, MD Gastrointestinal Oncology Service,
Department of Medicine, Memorial Sloan Kettering Cancer Center,
New York, NY, USA

Chrisann Kyi, MD Department of Internal Medicine,
New York-Presbyterian Hospital, Weill Cornell Medical
College of Cornell University, New York, NY, USA

Telma Lança, PhD Instituto de Medicina Molecular,
Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Department of Immunology, The Netherlands Cancer
Institute (NKI), Amsterdam, The Netherlands

Roberto Lattanzio, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Qiao Li, PhD University of Michigan Comprehensive Cancer Center,
Ann Arbor, MI, USA

Department of Surgery, University of Michigan, Ann Arbor, MI, USA

Luigi Liborio Liberatore, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Paolo Lissoni, MD Italian Association of Integrated Medicine (AIMI),
Milan, Italy

Lorenzo Livi, MD Radiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Mauro Loi, MD Radiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Mariana Malvicini, PhD Gene Therapy Laboratory,
Department of Medicine, Hospital Universitario Austral,
Derqui-Pilar, Buenos Aires, Argentina

Gene Therapy Laboratory, School of Biomedical Sciences,
Austral University, Pilar, Buenos Aires, Argentina

Monica Mangoni, MD, PhD Radiotherapy Unit,
Department of Experimental and Clinical Biomedical Sciences,
University of Florence, Florence, Italy

Alberto Mantovani, MD Department of Immunology and Inflammation,
Clinical and Research Institute Humanitas, Rozzano, Milan, Italy

Department of Medical Biotechnology and Translational Medicine,
University of Milan, Milan, Italy

Marino Silvino, MD Centro Trasfusionale, Ospedale SS Trinità,
Popoli (PE), Italy

Maurie Markman, MD Department of Medical Oncology,
Cancer Treatment Centers of America, Philadelphia, PA, USA

Guillermo D. Mazzolini, MD, PhD Gene Therapy Laboratory,
Department of Medicine, Hospital Universitario Austral,
Derqui-Pilar, Buenos Aires, Argentina

Gene Therapy Laboratory, School of Biomedical Sciences,
Austral University, Pilar, Buenos Aires, Argentina

Icro Meattini, MD Radiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Giusy Messina, PhD Italian Association of Integrated Medicine,
Milan, Italy

Elizabeth A. Mittendorf, MD, PhD Department of Surgical Oncology,
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Antonio Mongelli, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Joseph F. Murphy, PhD Department of Cancer Therapeutics
and Immunology, Southern Research Institute, White Plains,
New York, USA

Luca Navarra, MD Dipartimento di Chirurgia Generale,
Ospedale SS Trinità, Popoli (PE), Italy

Hans W. Nijman, PhD Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Ning Ning, MD Department of General Surgery, Chinese PLA General Hospital, Beijing, China

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

Rimas J. Orentas, PhD Immunology Section, Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, National Institute of Health, Bethesda, MD, USA

Qin Pan, MD, PhD Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

State Key Laboratory of Virology, Department of Immunology, Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University School of Medicine, Wuhan, Hubei Province, China

Patrizia Pellegrini, PhD Department of Medicine, National Research Council-Institute of Translational Pharmacology, Istituto di Farmacologia Traslazionale (IFT), Consiglio Nazionale delle Ricerche (CNR), Unità Operativa di Supporto (UOS), L'Aquila, Italy

George E. Peoples, MD Department of Surgery, Cancer Vaccine Development Program, Brooke Army Medical Center, Fort Sam Houston, TX, USA

Shraddha S. Rane, BTech, MRes, PhD The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK

Robert C. Rees, PhD, BSc (Hons), FIBiol, MRCPATH The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK

Nima Rezaei, MD, PhD Research Center for Immunodeficiencies, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

Department of Immunology, Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Manglio M. Rizzo, MD Gene Therapy Laboratory, School of Biomedical Sciences, Austral University, Pilar, Buenos Aires, Argentina

Gene Therapy Laboratory, Department of Medicine, Hospital Universitario Austral, Derqui Pilar, Buenos Aires, Argentina

Graziela Gorete Romagnoli, PhD Department of Microbiology and Immunology, Institute of Biosciences of Botucatu – UNESP, Univ Estadual Paulista, Botucatu, SP, Brazil

Joseph D. Rosenblatt, MD Division of Hematology/Oncology,
Department of Medicine, Sylvester Comprehensive Cancer Center,
University of Miami Miller School of Medicine, Miami, FL, USA

Department of Microbiology and Immunology, University of Miami Miller
School of Medicine, Miami, FL, USA

Caroline Rousseau, MD, PhD Centre de Recherche en Cancérologie
de Nantes-Angers Inserm, Université de Nantes, Nantes, France

Department of Nuclear Medicine, University Hospital,
CHU de Nantes, Nantes, France

Department of Nuclear Medicine, ICO-René Gauducheau,
Saint-Herblain, France

Franco Rovelli, PhD Italian Association of Integrated
Medicine (AIMI), Milan, Italy

Mohamed Labib Salem, MSc, PhD Immunology and Biotechnology Unit,
Zoology Department, Faculty of Science, Center of Excellence in Cancer
Research (CECR), Tanta University, Tanta, Egypt

Enzo Secinaro Department of Medicine, Facoltà di Medicina,
Università Degli Studi G. D'Annunzio, Chieti-Pescara, Italy

Mahdi Shabani, PhD Monoclonal Antibody Research Center,
Avicenna Research Institute ACECR, Tehran, Iran

Irina Zh. Shubina, PhD Laboratory of Cell Immunity, N.N. Blokhin
Russian Cancer Research Center RAMS, Moscow, Russia

Imran Siddiqui, PhD Department of Immunology and Inflammation,
Clinical and Research Institute Humanitas, Rozzano, Milan, Italy

Bruno Silva-Santos, PhD Department of T Cell Differentiation and
Tumor Targeting, Instituto de Medicina Molecular, Lisbon, Portugal

Instituto de Medicina Molecular, Faculdade de Medicina,
Universidade de Lisboa, Lisbon, Portugal

Ryszard Smolarczyk, PhD Center for Translational Research and
Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

Aleksander Sochanik, PhD Center for Translational Research and
Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

Mariangela Sottili, PhD Radiotherapy Unit, Department of Experimental
and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Peter L. Stern, PhD Women's cancer Institute of Cancer Sciences,
Paterson Building, University of Manchester, Manchester, UK

Jaimy Mariam Sultana Javad, MSc, PhD The John van Geest Cancer
Research Centre, School of Science and Technology, Nottingham Trent
University, Nottingham, UK

Stanisław Szala, PhD Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

Steve H. Thorne, PhD Division of Surgical Oncology, Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Fatma Vatansever, MD, PhD Wellman Center of Photomedicine, Massachusetts General Hospital, Boston, MA, USA

Department of Dermatology, Harvard Medical School, Boston, MA, USA

Vincenzo Vittorini, MD Dipartimento di Chirurgia Generale, Ospedale SS Trinità, Popoli (PE), Italy

Maurizio Vizioli, MD Dipartimento di Oncologia, Ospedale SS Trinità, Popoli (PE), Italy

Max S. Wicha, MD Internal Medicine Department, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA

Hengyi Xiao, MD, PhD Aging Research Group, Department of Geriatrics, State key laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Yingxin Xu, MD Department of General Surgery, Chinese PLA General Hospital, Beijing, China

Jianda Yuan, MD, PhD Immunology Program, Ludwig Center for Cancer Immunotherapy, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center New York, New York, NY, USA

Amir-Hassan Zarnani, PhD Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran

Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Ling Zhang, PhD Immunology Section, Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, National Institute of Health, Bethesda, MD, USA

Yu Zhang, MD Division of Hematology/Oncology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA

Abbreviations

3'-UTR	3'-untranslated region
3D	Three-dimensional
3-MA	3-Methyladenine
4-OHT	4-Hydroxytamoxifen
5AC	5-Azacytidine
Ab	Antibody
ABC	Adenosine triphosphate-binding cassette
Abs	Antibodies
AC	Adenocarcinoma
ACC	Acinar cell carcinoma
ACC	Adenoid cystic carcinoma
Ad5	Adenovirus serotype 5
ADCC	Antibody-dependent cellular cytotoxicity
ADCP	Antibody-dependent cellular phagocytosis
ADP	Anti-adipophilin
Ag	Antigen
AHR	Aryl hydrocarbon receptor
AIA	Ag-induced arthritis
AICD	Activation-induced cell death
AIDS	Acquired immune deficiency syndrome
AIF	Aapoptosis-inducing factor
AILT	Angioimmunoblastic T-cell lymphoma
AIRC	Italian Association for Cancer Research
AIRE	Autoimmune regulator
ALK	Anaplastic large cell lymphoma kinase
ALL	Acute lymphoblastic leukemia
ALP	Alkaline phosphatase
alphaGalCer	Alpha-galactosylceramide
ALPS	Autoimmune lymphoproliferative syndrome
AML	Acute myeloid leukemia
ANCs	Absolute neutrophil counts
ANN	Artificial neural network
ANT	Adenine nucleotide translocase
APC	Antigen-presenting cells
APCP	Adenosine 5'-(α , β -methylene) diphosphate
APCs	Antigen-presenting cells

APECED	Autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy
APL	Acute promyelocytic leukemia
APM	Antigen presentation machinery
APS-1	Autoimmune polyendocrine syndrome type I
ARB	Average relative binding
ARDS	Acute respiratory distress syndrome
ASCs	Adult stem cells
ASM	Acid sphingomyelinase
ASPS	Alveolar soft part sarcoma
ATCL	Anaplastic large cell lymphoma
ATLL	Adult T-cell lymphoma/leukemia
ATM	Ataxia telangiectasia mutated
ATO	Arsenic trioxide
ATP	Adenosine triphosphate
ATR	Ataxia telangiectasia/Rad3-related kinase
ATRA	All-trans retinoic acid
B SLL/CLL	B-cell small lymphocytic lymphoma/chronic lymphocytic lymphoma
BAFF	B-cell activating factor
BALs	Bronchoalveolar lavage
BCA	Basal cell adenocarcinoma
BCC	Basal cell carcinoma
BCG	Bacillus Calmette-Guérin
BCR	B-cell antigen receptor
BER	Base excision repair
bFGF	Basic fibroblast growth factor
BLI	Bioluminescence imaging
Bregs	Regulatory B cells
BSO	Buthionine sulfoximine
BTK	Bruton's tyrosine kinase
BTLA	B- and T-lymphocyte attenuator
C/EBP β	CCAT/enhancer-binding protein b
CAFs	Cancer-associated fibroblasts
CaP	Prostate cancer
CARD	Caspase-recruitment domain
CBA	Cytometric bead array
CBR	Clinical benefit response
CC	Choriocarcinoma
CC	Chromophobe carcinoma
CCS	Clear cell sarcoma
CD	Clusters of differentiation
CD40-B	CD40-activated B
CD40L	CD40 ligand
CDC	Complement-dependent cytotoxicity
c-FLIP	Cellular FLICE-inhibitory protein
CFSE	Carboxyfluorescein diacetate succinimidyl ester
CGN	Chromogranin

CHL	Classic Hodgkin lymphoma
CHS	Contact hypersensitivity
CIA	Collagen-induced arthritis
CIC/CRI	Cancer Immunotherapy Consortium of the Cancer Research Institute in the USA
CIHR	Canadian Institutes of Health Research
CIMT	Cancer Immunotherapy
CIP	CIMT Immunoguiding Program
CK	Cytokeratin
CLA	Cutaneous lymphocyte-associated antigen
CLEC9A	C-type lectin domain family 9A
CLL	Chronic lymphocytic leukemia
CLRs	C-type lectin and lectin-like receptors
CLRs	C-type lectin receptors
CMA	Chaperone-mediated autophagy
CMC	Chronic mucocutaneous candidiasis
CML	Chronic myeloid leukemia
CNS	Central nervous system
Con	Concanavalin
CP	Core particle
CpG-A ODN	CpG-A oligodeoxynucleotide
CpG-ODN	CpG oligodeoxynucleotide
CPS	Cancer Prevention Study
CQ	Chloroquine
CR	Complete remission
CRC	Colorectal cancer
CRCC	Clear RCC
CRDs	Cysteine-rich domains
CrmA	Cytokine response modifier A
CRP	C-reactive protein
CRT	Calreticulin
CS	Classic seminoma
CS&T	Cytometer setup and tracking
CSC	Cancer stem cell
CSF-1	Colony-stimulating factor
CSF-1R	CSF-1 receptor
CSF3R	Colony-stimulating factor 3 receptor
CSR	Class switch recombination
c-state	Cytosolic state
CTC	Circulating tumor cells
CTL	Cytotoxic T lymphocyte
CTS	Cathepsins
CTVT	Canine transmissible venereal tumor
CVID	Common variable immunodeficiency
Cyt	Cytochrome
DAMP	Damage-associated molecular pattern
DC	Dendritic cells
DCC	Deleted in colorectal cancer